As the life expectancy of Americans...

As the life expectancy of Americans has increased, in such a manner has the prevalence of heart failure, which now accounts for approximately 20 percent of all hospitalizations for patients more than 65 years of age. A substantial number of changes have emerg in the management of heart failure from one side of to the other the past decade. Jessup and Brozena summarize these changes in a broad-based review of this used by all disease.

The authors note that symptomatic heart failure has a worse prognosis than greatest in quantity types of cancer in the United States, with a one-year mortality rate of approximately 45 percent Although subject of attention results have shown that deaths related specifically to heart failure have decreased with recent management, the overall survival rate has not significantly improved.

The pathophysiology of heart failure is quite webwork In addition to the well-known structural and functional abnormalities of the heart itself, there are a legion of abnormally activated neurohormonal hypothesiss (e.g., changes in renin-angiotensin-aldosterone axis, sympathetic nervous a whole natriuretic peptides, and endogenous vasodilators and other agents). Furthermore, greatest in number patients with heart failure are somewhat old and have at least individual coexisting chronic illness.

Remodeling of the left ventricle is belonging to all in patients with heart failure. First, the chamber hypertrophies, then dilates and becomes more spherical, which has deleterious consequences on diastolic and systolic function. Elevated end-diastolic urgencys can lead to mitral regurgitation and atrial draw out which then can cause atrial fibrillation, compounding the ventricular dysfunction.

The authors review a staged approach to the management of this complexus disease. In this approach, patients with stage A heart failure are at high risk of heart failure, nevertheless they do not have symptoms of heart failure or evidence of structural heart disease. This stage includes patients with hypertension, diabetes, coronary artery disease, previous prospect to cardiotoxic drugs, or a family history of cardiomyopathy. ascendency of hypertension, coronary artery disease, and diabetes are the chief targets for early intervention. The authors praise the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blocker (ARBs) in patients who are at risk, in order to obstruct the maladaptive remodeling that is the hallmark of early disease.

At stage B structural heart disease is apparent (ventricular remodeling, with diastolic dysfunction or dejected ejection fraction), but symptoms have not notwithstanding developed. Patients in this stage would be considered to have of recent origin York Heart Association (NYHA) class I symptoms, including those with left ventricular hypertrophy previous myocardial infarction, valvular heart disease, or left ventricular systolic dysfunction. The use of ACE inhibitors or ARBs is indicated in all patients in this stage. The authors note that no particular ACE inhibitor and no specific high or subdued dose has been proved superior in the treatment of heart failure. Modification of lifestyle factors, like as weight monitoring, medication compliance, moderation of alcohol consumption, avoidance of nonsteroidal anti-inflammatory physics and scheduled exercise, is emphasized.

Patients in stage C have symptoms that could be classified as NYHA class I, II, III, or IV. Beta blocker are now widely advocated for use in all patients with symptomatic heart failure and also in many presymptomatic patients. The authors note that short-term exacerbations of heart failure symptoms may initially come about with the use of beta blocker unless studies have uniformly shown improvement in long-term survival with the use of these agents. Diuretics and dietary sodium restriction are commonly engageed to deal with the book overload that accompanies advancing heart failure.

Aldosterone antagonists (eg spironolactone) and digoxin are other options for medical treatment of heart failure after ACE inhibitors and beta blocker have been appropriately engrossed The authors discuss nonpharmacologic measures, similar as cardiac resynchronization for patients with significant interventricular conduction defects; coronary revascularization for ischemic patients; and ventricular assist devices in end-stage patients who are candidates for transplantation.

Jessup M Brozena s Heart failure. N Engl J M May 15 2003;348:2007-18

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group